161 related articles for article (PubMed ID: 23207619)
1. Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Cetin B; Benekli M; Oksuzoglu B; Koral L; Ulas A; Dane F; Turker I; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Isıkdogan A; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
Onkologie; 2012; 35(12):740-5. PubMed ID: 23207619
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
[TBL] [Abstract][Full Text] [Related]
5. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
7. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
[TBL] [Abstract][Full Text] [Related]
8. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
10. High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Rhee J; Han SW; Cha Y; Ham HS; Kim HP; Oh DY; Im SA; Park JW; Ro J; Lee KS; Park IH; Im YH; Bang YJ; Kim TY
Breast Cancer Res Treat; 2011 Jan; 125(1):107-14. PubMed ID: 20936340
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
Kroep JR; Linn SC; Boven E; Bloemendal HJ; Baas J; Mandjes IA; van den Bosch J; Smit WM; de Graaf H; Schröder CP; Vermeulen GJ; Hop WC; Nortier JW
Neth J Med; 2010 Sep; 68(9):371-6. PubMed ID: 20876920
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
Glück S; Castrellon A
Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
15. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Ryan Q; Ibrahim A; Cohen MH; Johnson J; Ko CW; Sridhara R; Justice R; Pazdur R
Oncologist; 2008 Oct; 13(10):1114-9. PubMed ID: 18849320
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
Osako T; Ito Y; Takahashi S; Tokudome N; Iwase T; Hatake K
Cancer Chemother Pharmacol; 2008 Jun; 62(1):159-64. PubMed ID: 17882419
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib for the treatment of HER2-overexpressing breast cancer.
Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
[TBL] [Abstract][Full Text] [Related]
20. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
